Abstract： Perampanel, one of the third-generation antiseizure drugs, can non-competitively bind a-amino-3- hydroxyl-5-methyl-4-isoxazole-propionate receptor. It has been approved for both monotherapy and adjunctive treatment of patients≥4 years old with focal epilepsy (with or without secondary generalized seizures) in China. Researches on treatment of perampanel in special population such as children, the elderly and women have been constantly updated, but summaries on them are lacked recently. This review summarizes the latest clinical studies on the above-mentioned population, providing reasonable basis for clinicians.